Solutions for
- - - Aiosyn develops software solutions that use state-of-the-art computational pathology technology. Our AI-powered pathology algorithms are integrated in standard pathology workflows to enable diagnostics and clinical studies anywhere and anytime.
- - - Clinical Diagnostics
      
      We develop algorithms that improve the digital pathology workflow and certified clinical diagnostic algorithms that augment pathologists.
    - Learn more
  - - Life Sciences
      
      We support CROs and biopharma with AI-powered solutions to identify novel pathology-based biomarkers that can accelerate drug development.
    - Learn more
  - - AI & Data Providers
      
      We enable AI and data providers to ensure the use of only high-quality, artifact-free images.
    - Learn more
AI Pathology Software
- - - We specialize in deep learning solutions for pathologists, focusing on cancer and chronic kidney disease biomarkers. Our AI-powered technology improves the digital pathology workflow and facilitates informed decision-making in drug development and clinical diagnostics.
- - - Automated Quality Control
      
      We provide an AI-powered solution for automated quality control of digital histology slides in the pathology workflow.
    - Learn more
  - - Mitotic figure counting
      
      We provide an AI-powered solution to aid clinical and research labs with the identification of mitotic figures in H&E sections.
    - Learn more
  - - NephroPath platform
      
      Aiosyn’s NephroPath platform harnesses AI-powered computational pathology algorithms that provide objective quantification of kidney lesion scores.
    - Learn more
Services
- External Digital Slide Quality Assessment
- Kidney Analysis Services
News & Resources
About

Contact

Publication

Quantitative Image Analysis Uncovers the Efficacy of the Selective Endothelin A Receptor Antagonist Atrasentan in a Rat Model of IgA Nephropathy

By Thomas de Bel

26 October, 2024

Authors

François Briand, Estelle Grasset, Nicole Endlich, VedranDrenić, Blazej Dolicki, Thomas de Bel, Thierry Sulpice

Abstract

Our aim was to validate and optimize a rat model of IgA nephropathy for drug efficacy studies using quantitative image analysis of kidney. To demonstrate the accuracy of our imaging methods, we evaluated atrasentan, a selective Endothelin A receptor Antagonist currently evaluated in phase III clinical trials.

See the full poster

By Thomas de Bel

AI Scientist

More about the author

By Błażej Dolicki

AI Engineer

More about the author

Aiosyn develops software solutions that use state-of-the-art computational pathology technology. Our AI-powered pathology algorithms are integrated in standard pathology workflows to enable diagnostics and clinical studies anywhere and anytime.

Clinical Diagnostics

Life Sciences

AI & Data Providers

We specialize in deep learning solutions for pathologists, focusing on cancer and chronic kidney disease biomarkers. Our AI-powered technology improves the digital pathology workflow and facilitates informed decision-making in drug development and clinical diagnostics.

Automated Quality Control

Mitotic figure counting

NephroPath platform

Publication

Quantitative Image Analysis Uncovers the Efficacy of the Selective Endothelin A Receptor Antagonist Atrasentan in a Rat Model of IgA Nephropathy

Authors

Abstract

More Publication

Quantitative Image Analysis Reveals the Benefits of Dapagliflozin on Glomerulosclerosis, Podocytes Effacement and Kidney Fibrosis in the SDT Fatty Rat Model of Diabetic Nephropathy

Convolutional Neural Networks for the Evaluation of Chronic and Inflammatory Lesions in Kidney Transplant Biopsies

Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge

Deep learning in histopathology: the path to the clinic

Deep learning enables fully automated mitotic density assessment in breast cancer histopathology

Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists

Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study

Deep Learning–Based Histopathologic Assessment of Kidney Tissue